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Resum. Malgrat que la relació inversa entre les con-
centracions baixes de colesterol associat a lipoproteïnes 
d’alta densitat i l’increment del risc de patir una malaltia 
cardiovascular està comunament acceptada, l’ús d’alguns 
fàrmacs que incrementen les concentracions de colesterol 
d’HDL no s’ha trobat associat a una reducció en l’aparició 
d’episodis cardiovasculars. Es considera que el transport 
revers de colesterol (RCT) és el principal responsable de 
l’efecte cardioprotector de l’HDL, estimulant el flux de 
colesterol des dels macròfags de les cèl·lules escumoses 
en la lesió arterioscleròtica cap a fetge on és eliminat par-
cialment en femtes. A més del RCT, les HDL tenen altres 
propietats cardioprotectores degudes als seus efectes 
antioxidant i antiinflamatori. Els estudis en ratolins modi-
ficats genèticament han permès demostrar que aquestes 
funcions de les HDL estan associades a la susceptibilitat a 
l’arterioesclerosi i suggereixen que fàrmacs que les puguin 
estimular podrien ser considerats com a noves estratègies 
terapèutiques per a prevenir el desenvolupament de la pla-
ca arterioescleròtica i el risc d’episodis cardiovasculars. El 
potencial antitumorogènic de les HDL és una àrea d’inves-
tigació recent. Aquests tipus d’investigacions són essenci-
als per a poder traslladar els resultats obtinguts a humans. 
Els estudis més recents indiquen que l’augment del flux de 
colesterol des dels macròfags fins a les HDL, el primer pas 
del RCT, està inversament relacionat amb l’aparició d’epi-
sodis cardiovasculars. Per tant, la majoria d’estudis actuals 
van enfocats a millorar les propietats cardioprotectores de 
les HDL, més que no pas a  intentar augmentar les concen-
tracions de colesterol d’HDL.
Abstract. Although significant evidence supports the 
concept that low high density lipoprotein cholesterol 
(HDL-C) is associated with an increased risk of cardiovas-
cular disease (CVD), the failure of several HDL-targeted 
therapies to reduce CVD has cast doubts on the HDL-C 
hypothesis. Reverse cholesterol transport (RCT) is current-
ly thought to be a major HDL cardioprotective property by 
which HDL promotes cholesterol efflux from macrophage 
foam cells and delivers that cholesterol to the liver, from 
where it will be partly eliminated through bile and feces. 
Beyond RCT, HDL exhibits other cardioprotective properti-
es, such as antioxidant and anti-inflammatory effects. Data 
from genetically-engineered mice indicate that these HDL 
functions are closely associated with atherosclerosis sus-
ceptibility, thereby suggesting that the promotion of HDL 
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functional properties may be considered a novel therapeu-
tic strategy to reduce the atherosclerotic plaque burden 
and subsequent cardiovascular events. Furthermore, the 
potential anti-tumorigenic role of HDL is currently under 
investigation. This research has been essential for trying to 
translate experimental results obtained in mice to humans. 
The results of several recent human studies indicate that 
enhanced macrophage cholesterol efflux, the first step of 
RCT, is inversely associated with CVD events. Therefore, 
the current research is focused on improving HDL function 
rather than simply targeting HDL-C levels. 
Abbreviations. HDL: high density lipoprotein; LDL: low 
density lipoprotein; CVD: cardiovascular disease; CETP: 
cholesteryl ester transfer protein; ACAT: cholesterol acyl 
transferase; PLTP: phospholipid transfer protein; HL: he-
patic lipase; EL: endothelial lipase; ApoA-I: apolipoprotein 
A-I; ABC: ATP-binding cassette; RCT: reverse cholesterol 
transport; LXR: liver X receptor; PPAR: peroxisome prolife-
rator-activated receptor; NPC1L1: niemann-Pick C1-Like 1; 
CYP7A1: cytochrome P450 family 7 subfamily 1; PON1: pa-
raoxonase/arylesterase 1; PAF-AH: platelet-activating fac-
tor-acetylhydrolase; SIRT: NAD+-dependent deacetylase 
sirtuin; SERM: selective estrogen receptor modulators; SFA: 
saturated fatty acids; PUFA: polyunsaturated fatty acids; 
TAM: tamoxifen; RAL: raloxifene; TOR: toremifene; ER: es-
trogen receptor; HPA: hypothalamic-pituitary-adrenal; CRF: 
corticotrophin releasing factor; CORT: corticosterone
Introduction
The current concept that high-density lipoprotein (HDL) 
protects against cardiovascular disease (CVD) is based on 
abundant preclinical and epidemiological data. Originally, 
the main explanation was associated with the ability of 
HDL to induce cholesterol efflux from macrophage foam 
cells in atherosclerotic lesions (Glomset, 1968). Historically, 
the macrophage cholesterol efflux has been considered 
the main HDL antiatherogenic function. However, rever-
se cholesterol transport (RCT) is a complex pathway and 
macrophage cholesterol efflux is only considered the first 
step of the pathway. This antiatherogenic pathway may 
be regulated at different steps, such as (i) the macrophage 
cholesterol efflux, (ii) the transport of cholesterol through 
the plasma compartment, (iii) the liver uptake, (iv) the he-
patobiliary excretion, and (v) the excretion from the body 
(see Figure 1 for details). 
The failure of various HDL-targeted therapies to redu-
ce CVD has cast doubts on the HDL hypothesis. Two large 
trials (ILLUMINATE and dal-OUTCOMES) with cholesteryl 
ester transfer protein (CETP) inhibitors were stopped for 
disappointing results or reason of futility (Barter and Rye, 
2012), and a large Mendelian randomization study showed 
that a single-nucleotide polymorphism (SNP) in the endot-
helial lipase (EL) gene did not affect the risk of myocardial 
infarction despite increasing HDL cholesterol (HDL-C) (Voight 
et al., 2012). Therefore, the inverse relation between cardio-
vascular risk and HDL is no strictly related to the mass of cho-
lesterol transported by HDL (Rader and Hovingh, 2014). HDL 
comprises a complex mixture of heterogeneous lipoproteins 
ranging from nascent preβ-HDL particles to mature HDL 
spherical particles. Apolipoprotein (apo) A-I is the main HDL 
protein and significant evidence reveals that most HDL an-
tiatherogenic properties depend on apoA-I content (Mineo 
and Shaul, 2012). Among these anti-atherosclerotic proper-
ties, the best recognized is the ability of HDL to stimulate ef-
flux of excess cholesterol from macrophage foam cells, and 
consequently this is the most evaluated mechanism (Camont 
et al., 2011). This efflux to HDL occurs via different pathways, 
the most efficient ones being mediated by two cholesterol 
transporters, transmembrane ATP-binding cassette (ABC): 
ABCA1 and ABCG1. ABCA1 promotes cholesterol transport 
to nascent preβ-HDL and lipid free apoA-I, whereas ABCG1 
facilitates the efflux to mature α-migrating HDL. Macropha-
ge ABCA1 and ABCG1 form the primary route of cholesterol 
efflux and, therefore, start the macrophage-to-feces RCT (Fi-
gure 1). The results of several recent studies indicate that 
stimulation of macrophage cholesterol efflux to HDL medi-
ated by ABCA1 transporter is inversely associated with the 
incidence of atherosclerotic CVD events, thereby indicating 
the importance of this function as biomarker for predicting 
CVD risk (Rohatgi et al., 2014; Saleheen et al., 2015).
The efflux of cellular cholesterol to HDL initiates RCT 
in all tissues, but the fraction that originates from the ma-
crophage foam cells located in the intima is considered the 
main RCT component directly involved in atherosclerosis 
(Cuchel and Rader, 2006). An assay for measuring in vivo 
macrophage-to-feces RCT by tracing the reverse [3H]-cho-
lesterol transport from lipid-laden macrophages to feces 
in mice was developed (Rader et al., 2009). The method 
has been used to study the role of different therapies and 
pathways relevant for RCT and HDL-mediated atheropro-
tection (Escola-Gil et al., 2009; Annema and Tietge, 2012). 
However, this method is only applicable in animal models 
and, for ethical issues, seems impossible to apply in hu-
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mans. Some studies are in process to discover the way to 
evaluate the entire RCT pathway in humans such as the use 
of [3H]-cholesterol/albumin complexes or [2,3-13C2]-cho-
lesterol but the application of these assays are still awaited 
(Schwartz et al., 2004; Turner et al., 2012).
HDL targets 
With the creation and detailed analysis of geneti-
cally-modified mice, a solid body of new information 
emerged on the mechanisms controlling the RCT pathway. 
Indeed, the atheroprotective role of apoA-I has been cor-
roborated in transgenic mice (Rubin et al., 1991). Such 
beneficial effects of apoA-I on the development of athe-
rosclerosis can be related to its stimulatory effect on ma-
crophage-to-feces RCT, which has been demonstrated 
both in transgenic mice expressing human apoA-I (hApoA-I) 
(Zhang et al., 2003) and in wild-type mice intraperitoneally 
administered with a dose of hApoA-I (Lee-Rueckert et al., 
2011). The generation of genetically-modified mice for 
ABCA1, apoA-II, CETP, hepatic lipase (HL) and EL has permit-
ted to identify potential molecular targets for modulating 
macrophage-specific RCT and HDL antioxidant activity (see 
Table 1 for a summary). 
ATP-binding cassette transporter A1 (ABCA1)
ABCA1 is present in liver, intestine and others periphe-
ral tissues, particularly in macrophages. ABCA1 is required 
	
Figure 1 legend. Schematic diagram of reverse cholesterol transport pathway. ApoA-I is synthesized by liver and small intestine, ac-
quires phospholipids and become nascent partially lipidated preβ-HDL particles. Preβ-HDL particles acquire free cholesterol from 
macrophages via adenosine triphosphate-binding cassette (ABC) A1 transporter. Free cholesterol is converted into cholesteryl ester 
within the HDL particle by the action of lecithin:cholesterol acyltransferase (LCAT), thereby resulting in mature HDL. ApoA-I is the 
major HDL protein and activates LCAT, whereas apoA-II, the second HDL protein, displaces apoA-I form HDL particles. The scavenger 
receptor type BI (SR-BI) and ABCG1 facilitate the cholesterol efflux process from macrophages to mature HDL. Phospholipid transfer 
protein (PLTP) promotes the transfer of phospholipids and free cholesterol from triglyceride-rich lipoproteins into HDL, producing a 
remodelling process by which preβ-HDL particles can be generated. Furthermore, PLTP may promote the fusion of smaller HDL parti-
cles and subsequent generation of larger HDL particles. Endothelial lipase (EL) and hepatic lipase (HL) hydrolyse HDL triglycerides and 
phospholipids, thereby converting large HDL particles to smaller ones. HDL-cholesteryl ester can be transferred to VLDL or LDL by cho-
lesteryl ester transfer protein (CETP) and returned to the liver through low-density lipoprotein receptor (LDLR) or other receptors. The 
liver also selectively takes up HDL-associated cholesterol via SR-BI. The liver ABCG5/G8 heterodimer is involved in cholesterol transport 
to bile. Niemann-Pick C1-like 1 (NPC1L1) is of crucial importance for absorbing macrophage-derived cholesterol in the small intestine. 
Cholesterol may also be excreted back to the lumen by the intestinal ABCG5/G8 heterodimer.
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for the maintenance of plasma HDL levels via preβ-HDL for-
mation (Figure 1), which are among the main acceptors of 
cholesterol efflux (Basso et al., 2003). Macrophage-selecti-
ve inactivation of ABCA1 promotes atherosclerotic lesions 
without affecting plasma HDL levels (Aiello et al., 2002; 
Francone et al., 2005). We investigated the in vivo role of 
ABCA1 in macrophage-specific RCT by using the wild-type 
ABCA1+/+, ABCA1+/− and ABCA1-deficient (ABCA1−/−) mice 
(Calpe-Berdiel et al., 2005). Whole body cholesterol balan-
ce did not differ among genotypes, indicating that total RCT 
does not seem to be affected by ABCA1 or HDL deficien-
cy. However, a direct relationship was observed between 
ABCA1 gene dose and the amount of macrophage-derived 
[3H]-cholesterol in plasma. Importantly, ABCA1−/− mice 
had a significantly reduced excretion of fecal [3H]-choles-
terol (Calpe-Berdiel et al., 2005). In line with these findings, 
selective inactivation of ABCA1 in macrophages also impai-
red macrophage-to-feces RCT (Wang et al., 2007). Overall, 
these findings confirm the crucial role of ABCA1 in this athe-
ropretective mechanism of HDL (Lee-Rueckert et al., 2016).
Apolipoprotein A-II
In contrast with the cardioprotective effect of apoA-I, 
the overexpression of mouse and human apoA-II has usually 
been found to be proatherogenic (Warden et al., 1993; Esco-
la-Gil et al., 1998).  However, the role of apoA-II on major HDL 
functions remains unclear. One of the mechanisms by which 
apoA-II cause atherosclerosis may be an impaired ability of 
HDL to protect against low density lipoprotein (LDL) oxida-
tion, as reported in mouse apoA-II transgenic mice (Caste-
llani et al., 1997). We investigated the potential of human 
apoA-II (hApoA-II) transgenic HDL to protect against oxida-
tive modification of apoB-containing lipoproteins (Escola-Gil 
et al., 2000). We found a significant increase in the amount 
of aortic antigens related to LDL oxidation in transgenic mice 
overexpressing hApoA-II. HDL of transgenic mice failed to 
protect the apoB-containing lipoproteins from oxidation, in-
cluding very low-density lipoprotein (VLDL) and LDL. Human 
apoA-II-containing HDL also showed a decreased content of 
the main HDL antioxidant enzymes paraoxonase/arylestera-
se 1 (PON1) and platelet-activating factor-acetylhydrolase 
(PAF-AH).  Incubating isolated hApoA-II with control plasma 
at 37ºC decreased PON1 activity in plasma and HDL. The dis-
placement of PON1 by physiologic concentrations of hApoA-
II could explain why PON1 is mostly found in HDL particles 
without apoA-II, as well as, the lack of antiatherogenic pro-
perties of apoA-II-enriched HDL (Ribas et al., 2004). In an in-
dependent study, we investigated the effects of hApoA-II on 
the entire RCT pathway by using transgenic mice under chow 
or an atherogenic diet. On the chow diet, hApoA-II overex-
pression accelerated the transfer of macrophage-derived 
cholesterol to liver and feces. However, the magnitude of 
macrophage-to-feces RCT did not differ between transgenic 
and control mice fed the atherogenic diet. Taken together, 
our results indicate that hApoA-II exerts its proatherogenic 
effect by counteracting antioxidant properties of HDL rather 
than by impairing macrophage-to-feces RCT (Escola-Gil et 
al., 2000; Ribas et al., 2004; Rotllan et al., 2005).
Cholesteryl ester transfer protein (CETP)
CETP promotes the removal of cholesteryl ester from 
HDL in heteroexchange for triglycerides derived from LDL, 
HDL-C
HDL antioxidant 
potential
Macrophage-to-feces 
RCT
ABCA1 deficiency (Cal-
pe-Berdiel et al., 2005) ↓
Non determined
↓
Human Apo A-II overex-
pression (Ribas et al., 2004; 
Rotllan et al., 2005)
↓
↓
=
CETP overexpression (Rot-
llan et al., 2008) ↓ =
=
HL and EL overexpression 
(Escola-Gil et al., 2013b) ↑ ↑ ↑
Table 1. Assays of HDL function in genetically-modified mice.
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VLDL or chylomicrons (Figure 1). CETP transgenic mice, 
which naturally do not have this transporter protein, showed 
increased susceptibility to atherosclerosis, although the ef-
fects of CETP on CVD in human studies remain unclear (Tall, 
1993; de Grooth et al., 2004). We determined the influence 
of CETP activity on the two major antiatherogenic functions 
of HDL by using transgenic mice overexpressing CETP. The 
magnitude of macrophage-derived cholesterol in liver and 
feces did not differ between CETP transgenic mice and con-
trol mice and this was independent of the diet used (chow 
or atherogenic). Furthermore, the injection of endogenous 
CETP-expressing macrophages did not alter macrophage 
RCT in control mice. HDL from CETP-expressing mice protec-
ted LDL from oxidative modification at similar levels that did 
the HDL from control mice (Rotllan et al., 2008). Although 
we did not find significant evidence that CETP affected the-
se major HDL functions, adenovirus-mediated human CETP 
expression promoted the macrophage-dependent RCT rate 
(Tanigawa et al., 2007; Tchoua et al., 2008). In any event, 
these results would not predict the increased atherosclero-
sis susceptibility of CETP transgenic mice. 
Hepatic lipase (HL) and endothelial lipase (EL)
HL and EL are part of the triglyceride lipase family and 
differ in their hydrolytic activities. EL is mainly a phospho-
lipase enzyme while HL has phospholipase and triglyceri-
de lipase activities; both enzymes may convert large HDL 
to smaller HDL (Yasuda et al., 2010). HL- and EL-deficien-
cy in mice caused a significant increase on HDL lipid and 
apoA-I levels (Ishida et al., 2003). A physiologically impor-
tant question is whether HL and EL activities alter HDL car-
dioprotective functions. We evaluated the effects of HL 
and EL deficiency on macrophage-to-feces RCT pathway in 
vivo, the susceptibility to oxidation of HDL, and its ability 
to protect against LDL oxidation (Escola-Gil et al., 2013b). 
As expected, both HL- and EL-deficiency caused an increase 
in cholesterol and phospholipids associated to HDL and an 
increase in HDL size. ApoA-I and PAF-AH were also incre-
ased in both HL- and EL-deficient mice but no changes in 
PON1 activity were found. These changes did not correlate 
with alterations in the liver expression of enzymes involved 
in HDL metabolism. These genetically-modified mice dis-
played increased levels of macrophage-derived HDL-bound 
[3H]-cholesterol which was concomitant with increased 
levels of [3H]-cholesterol in feces. HDL from the HL- and 
EL-deficient mice was less prone to oxidation and had a 
higher ability to protect LDL from oxidation. These changes 
were more pronounced in the EL-deficient mice (Escola-Gil 
et al., 2013b). However, the role of HL- and EL-deficiency 
on atherosclerosis development provided divergent data 
Drug HDL-C
HDL antioxidant 
potential
Macrophage-to-feces 
RCT
Fibrates (Rotllan et al., 
2011) 
Fenofibrate
↑
Human apoAI, PLTP and 
liver ABCG5/G8 ↑ ↑
Gemfibrozil = Liver ABCG5/G8 ↑ =
LXR agonist (Calpe-Berdiel 
et al., 2008)
T0901317
↑
Liver ABCA1, ABCG5/G8 
and ABCG1 ↑ and  intesti-
ne ABCA1 and ABCG1 ↑
↑
SERMs (Fernandez-Suarez 
et al., 2016)
Tamoxifen
↓
Liver ABCG5/G8 ↓ ↓
Raloxifen ↓ =
Cholesterol absorbtion 
(Silvennoinen et al., 2012)
Ezetimibe
= Intestinal NPL1C1  ↓ ↑
PPARδ agonist GW0742 = Intestinal NPL1C1  ↓ ↑
Table 2. Effects of therapeutic agents on macrophage-to-feces RCT.
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since other HDL-independent biological properties of HL 
and EL, such as their role in modulating apoB-containing li-
poprotein catabolism, macrophage cholesterol uptake and 
inflammation influence (Annema and Tietge, 2011).
Pharmacology
RCT-enhancing therapies are currently considered a 
promising strategy for the prevention and treatment of at-
herosclerotic CVD. An important number of RCT-targeted 
drugs have been used in mice to test their effects on ma-
crophage-specific RCT in vivo. Some of these therapeutic 
approaches included fibrates, liver X receptor (LXR) activa-
tion and selective estrogen receptor modulators (SERMs), 
and cholesterol absorption inhibitors (Table 2).
Fibrates 
Fibrates are peroxisome proliferator-activated recep-
tors alpha (PPARα) agonists commonly used mainly in 
hypertriglyceridemic patients. Clinical effects of fibrates 
are attributed to their ability to reduce triglycerides and 
increase HDL-C levels (Fruchart et al., 1999; Staels et al., 
2008). Current guidelines recommend the use of fenofi-
brate for preventing cardiovascular disease, particularly 
for high-risk statin-treated patients with atherogenic dys-
lipidemia. Furthermore, fenofibrate appears to exert a 
stronger effect on plasma hApoA-I levels that other fibra-
tes. However, evidence that fibrates reduce mortality and 
morbidity associated with CVD is still unclear (Grundy et al., 
2004; Duez et al., 2005). 
Since HDL metabolism is regulated in an opposite manner 
by fibrates in wild-type rodents due to sequence divergen-
ces in the mouse Apoa1 promoter, our group investigated 
the effects of fibrates on the entire macrophage-depen-
dent RCT pathway in mice overexpressing hApoA-I, a model 
that elicits a humanized response to fibrates (Rotllan et al., 
2011). We used hApoA-I transgenic mice treated with gem-
fibrozil, fenofibrate or vehicle as control group. We found 
that fenofibrate increased significantly macrophage-deri-
ved plasma [3H]-cholesterol 24 and 48 hours after macro-
phage injection and the net fecal [3H]-cholesterol + bile acid 
excretion over 48h. Both fibrates increased mRNA levels 
of liver Ppara and two key liver genes involved in hepatic 
cholesterol transport to bile and feces, Abcg5 and Abcg8; 
but only fenofibrate induced lipid profile modifications. Af-
ter fenofibrate treatment, total plasma hApoA-I and HDL-C 
levels in female transgenic mice were higher than those of 
vehicle-treated mice. Fenofibrate also caused an increase in 
the amount of nascent preβ-HDL particles and plasma phos-
pholipid transfer protein (PLTP) activity, concomitant with 
an upregulation of Pltp and human APOA1 gene expression. 
In contrast, gemfibrozil did not affect these plasma parame-
ters and the macrophage-derived [3H]-cholesterol flux to 
plasma and feces of hApoA·l transgenic mice. Unlike gemfi-
brozil, fenofibrate also induced the generation of larger HDL 
particles, which were more enriched in cholesteryl esters, 
and promoted macrophage cholesterol efflux to plasma in 
vitro. None of the drugs affected net intestinal cholesterol 
absorption. These findings demonstrated that fenofibrate, 
but not gemfibrozil, promoted in vivo macrophage-specific 
RCT, thereby highlighting the differential action of this fi-
brate on HDL functionality. These data would be consistent 
with a protective clinical effect of fenofibrate that remains 
to be clearly demonstrated in interventional human studies 
(Rotllan et al., 2011).
Liver X activation
The LXR α and β are oxysterol-activated nuclear recep-
tors that regulate the expression of a number of genes in-
volved in RCT such as ABCA1, ABCG1, ABCG5, ABCG8 and 
cytochrome P450 7a1 (CYP7A1) (Repa et al., 2002). LXRα is 
expressed mainly in liver and secondarily in adrenal glands, 
intestine, adipose tissue, macrophages, lung and kidney. 
LXRβ is expressed in almost all tissues (Zelcer and Tonto-
noz, 2006). Overexpression of ABCG5/G8 or activation of 
LXRαβ results in increased hepatobiliary excretion of cho-
lesterol and increased fecal neutral sterol excretion (Yu et 
al., 2002a). Consistent with these findings, the inactivation 
of these two genes has opposite effects on sterol hepatobi-
liary excretion (Yu et al., 2002b).
Synthetic high-affinity LXRαβ agonists promote RCT 
from macrophages to feces in vivo despite having a limi-
ted impact on HDL-C levels. These specific activators also 
inhibit atherosclerosis progression, and even promote 
atherosclerosis regression in mice (Terasaka et al., 2003). 
The results of these studies support the concept that LXR 
activation promotes macrophage-specific RCT pathway by 
increasing biliary cholesterol excretion through ABCG5/G8 
upregulation (Yu et al., 2003).
We initially investigated the effects of ABCG5/G8 de-
ficiency as well as those of LXR agonist induction of RCT 
from mouse macrophages to feces in ABCG5/G8-deficient 
(ABCG5/G8-/-) and wild-type (ABCG5/G8+/+) mice (Cal-
pe-Berdiel et al., 2008). When [3H]-cholesterol-labeled 
mouse macrophages were injected intraperitoneally into 
the ABCG5/G8+/+ and ABCG5/G8-/- mice, we found an in-
Canyelles et al.
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creased radiolabeled HDL-bound [3H]-cholesterol after the 
label injection. However, not significant differences were 
found between the two groups in terms of [3H]-tracer in li-
ver, feces and bile acids. These findings were rather surpri-
sing, considering that disruption of ABCG5/G8 resulted in 
a marked reduction in biliary cholesterol levels. This could 
indicate an important role of the intestine in the model 
used in this study. Recent data suggest that the intestine 
may play an important role in excreting cholesterol from 
plasma to the intestinal lumen and feces. Then, we investi-
gated whether ABCG5/G8 were necessary for LXR-mediated 
induction of macrophage-specific RCT pathway by injecting 
the radiolabeled macrophages into the ABCG5/G8+/+ and 
ABCG5/G8-/- mice treated with or without the LXR agonist 
T0901317. Treatment with T0901317 increased liver ABCG5/
G8 expression, and was associated with a 2-fold increase in 
the fecal excretion of macrophage-derived [3H]-cholesterol 
of ABCG5/G8+/+ mice. However, the LXR treatment did not 
affect fecal [3H]-cholesterol excretion in ABCG5/G8-/- mice. 
We also determined the fate of [3H]-cholesterol from HDL by 
radiolabeling HDL with HDL-[3H]-cholesteryl oleate. Untre-
ated and T0901317-treated ABCG5/G8+/+ and ABCG5/G8-/- 
mice were injected intravenously with the radiolabeled HDL. 
Plasma clearance of intravenously injected [3H]-HDL was 
significantly slower in treated ABCG5/G8+/+ mice compared 
with untreated mice. However, LXR activation did markedly 
increase the recovery of HDL-derived [3H]-cholesterol in the 
feces of ABCG5/G8+/+ mice. Conversely, LXR agonists did not 
have the ability to increase fecal [3H]-cholesterol in ABCG5/
G8-/- mice (Calpe-Berdiel et al., 2008)
Our results demonstrated that ABCG5/G8 transporters 
are essential for the LXR agonist-mediated induction of RCT 
from macrophages to feces in vivo, thereby suggesting that 
upregulation of ABCG5/G8 may be an effective therapeu-
tic strategy to increase macrophage-to-feces RCT pathway 
and reduce atherosclerosis. However, LXR activators have 
undesired effects such as hepatic triglyceride accumula-
tion. Since LXRβ activation may target intestine, promo-
te macrophage RCT and prevent atherosclerosis, current 
efforts have focused on developing novel LXRβ-selective 
ligands that circumvent liver side effects. In contrast, so-
mewhat surprisingly, ABCG5/G8 deficiency in the mouse 
did not affect RCT from macrophages.
Selective estrogen receptor modulators (SERMs)
SERMs are non-steroidal molecules that can be estro-
gen-agonists or antagonists depending on the tissue targe-
ted and the kind of estrogen receptor (ER). Some examples 
of SERMs are tamoxifen (TAM) and toremifene (TOR), which 
are mainly used in breast cancer, and raloxifene (RAL), which 
is used for the treatment of osteoporosis in postmenopau-
sal women (Pickar et al., 2010). Beyond their therapeutics 
effects, SERMs also reduce cholesterol associated to LDL-C. 
This effect may be mediated by the decrease of cholesterol 
biosynthesis, the increase of the expression of LDL recep-
tor (LDLR), and the inhibition of cholesterol acyl transferase 
(ACAT) (Suarez et al., 2004; Cerrato et al., 2015). 
We have investigated whether the SERM-mediated in-
terference of cholesterol trafficking in macrophages may 
restrict cholesterol efflux to HDL and, consequently, im-
pair the cholesterol transport to feces in vivo. As expected, 
SERMs impaired intracellular acetylated LDL (acLDL)-deri-
ved cholesterol trafficking and cholesterol efflux in macro-
phages (Fernandez-Suarez et al., 2016). Human THP-1 ma-
crophages were loaded with [3H]-cholesterol-labeled acLDL 
in the presence of SERMs and cholesterol efflux to different 
acceptors was determined. TAM decreased apoA-I-medi-
ated cholesterol export in a dose-dependent manner, and 
HDL-mediated cholesterol efflux was also reduced. RAL and 
TOR also decreased apoA-I-mediated cholesterol efflux, but 
not the HDL-mediated cholesterol efflux. AcLDL markedly 
increased the protein levels of ABCA1 and ABCG1 in macro-
phages, whereas TAM, RAL and TOR had the opposite effect. 
The TAM-mediated effect on macrophage [3H]-cholesterol 
efflux was not related with its effects on cholesterol intra-
cellular trafficking. Therefore, SERMs impaired cholesterol 
export from THP-1 macrophages by two ways: lowering 
the availability of lipoprotein cholesterol and impairing the 
acLDL-mediated induction of ABCA1 and ABCG1. Moreo-
ver, SERMs effects were ER independent because ESR1 and 
ESR2 expression was undetectable in THP-1 macrophages 
and the addition of an ER down-regulator did not alter the 
effect of any SERM. These effects were also confirmed in hu-
man monocyte-derived macrophages. Importantly, when 
[3H]-cholesterol-loaded macrophages were intraperitone-
ally injected into mice, TAM, but not RAL, decreased the 
[3H]-cholesterol levels in serum, liver and feces. This effect 
was primarily attributable to the TAM-mediated reduction 
of the capacity of HDL to promote cholesterol mobilization 
from macrophages (Fernandez-Suarez et al., 2016). 
Cholesterol absorption inhibitors
Both macrophage- and non-macrophage-derived cho-
lesterol molecules are transferred through multiple steps of 
the reverse pathway to the intestine. On average, 50% of the 
cholesterol present in the intestinal lumen may be reabsor-
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bed, and the remainder will be ultimately excreted from the 
body as fecal cholesterol to complete the RCT pathway. The 
final regulatory steps of RCT that occur in the small intestine 
play an important role in determining the efficiency of cho-
lesterol absorption and thus can influence the rate of the 
total body RCT (Lee-Rueckert et al., 2013). We have recently 
investigated the effects of modulating the traffic of choles-
terol across the enterocyte on the rate of the specific itine-
rary of cholesterol from peripheral macrophages into feces. 
Therefore, interventions that inhibit cholesterol absorption 
including ezetimibe administration and PPARβ/δ activation 
with GW0742 increase the excretion of macrophage derived 
cholesterol in feces by reducing intestinal Niemann-Pick C1-
like protein 1 (NPC1L1) activity (Silvennoinen et al., 2012). 
Furthermore, certain pathophysiological conditions asso-
ciated with an increased risk of atherosclerotic CVD have 
been found to modify intestinal cholesterol absorption and 
affect the macrophage-to-feces RCT pathway (see Physiolo-
gical stress section for details).
Physiological and physiopathological 
states 
There are certain physiopathological states that may af-
fect HDL functionality such as stress or the immunological 
and inflammatory processes. HDL function has been also 
related with the potential anti-tumorigenic role of HDL.
Physiological stress
In humans, a relationship between stress and atheros-
clerosis has been found in some epidemiological studies 
under conditions that trigger different types of stress (Ro-
zanski et al., 1999).  Simulated stress conditions in mouse 
models are useful for search mechanisms implicated in at-
herosclerosis. Previously studies indicate that the dual role 
of stress on atherosclerosis depends on the type of stress: 
it can be accelerated or remain unaffected (Kumari et al., 
2003; Bernberg et al., 2009). We studied the rate macro-
phage-to-intestine RCT in mice exposed to restraint stress 
which mimics psychological stress in humans (Silvennoinen 
et al., 2012). We initially compared the results of a control 
mouse group without stress and mice exposed to physical 
restraint stress for 3 hours. Activation of hypothalamic-pi-
tuitary-adrenal (HPA) axis is the endocrine hallmark of 
stress and produce corticotrophin releasing factor (CRF) 
and corticosterone (CORT). In the stress group, CRF peaked 
and then rapidly returned to basal levels, whereas CORT le-
vels remained elevated in stress group due to inhibition of 
CRF by CORT. When [3H]-cholesterol-loaded macrophages 
were injected into the mice, stress did not affect choleste-
rol efflux from macrophages but inhibited intestinal choles-
terol absorption thus leading to accumulation of intestinal 
[3H]-cholesterol in the stressed mice.
Furthermore, administration of CORT, the stress hor-
mone in rodents, to non-stressed mice upregulated PPARα 
and downregulated NPC1L1 protein levels in the small in-
testine, fully reproducing the effect of stress on the rate of 
macrophage-to-intestine RCT in the non-stressed mice. The 
acceleration of RCT induced by stress was fully inhibited in 
mice pretreated with a cytochrome P450 inhibitor, metyra-
pone. No additive increase of macrophage-to-intestine RCT 
rate occurred if the stress mice were treated with ezetimibe 
or the PPARδ agonist GW0742 that blocks NPC1L1 action in 
the intestine (Silvennoinen et al., 2012). Overall, the results 
strongly indicated a functional connection between acute 
stress and decreased function of intestinal NPC1L1 via a 
mechanism likely mediated by PPARα, which is known to ne-
gatively regulate NPC1L1 expression in mice. Determination 
the macrophage-to-intestine RCT rate in PPARα knockout 
(KO) and LXRα KO mice exposed to stress shows that mere 
elevation of CORT by stress was not sufficient to promote 
macrophage-to-intestine RCT. Of note, we observed that 
the increase in the fecal excretion of macrophage-derived 
cholesterol induced by stress in mice was maintained for 7 
days of chronic exposure (Silvennoinen et al., 2012). 
Anti-tumorigenic role of HDL
Low levels of HDL-C have been associated with high risk 
of breast cancer (Ni et al., 2015). However the relationship 
between apoA-I and breast cancer remain unclear (Borg-
quist et al., 2016). ApoA-I has anti-inflammatory, antioxidant 
or anti-apoptotic properties. Some studies have demonstra-
ted that hApoA-I-containing HDL has potent anti-tumor acti-
vity in xenograft mouse models of ovarian cancer and mouse 
models of malignant melanoma and Lewis lung carcinoma. 
ApoA-I mimetic peptides, which mimic the distribution of 
the charge and structure of portions of apoA-I, are conside-
red as potential therapeutic agents for preventing a variety 
of inflammation-related diseases, including cancer. Indeed, 
two reports have demonstrated that the apoA-I mimetic 
peptide 4F significantly reduce tumor growth in xenograft 
mouse models of ovarian and colon cancer (Van Lenten et 
al., 2009; Su et al., 2010). 
We have recently investigated the effect of hapoA-I 
overexpression or administrated 4F in a validated mouse 
mammary tumor virus (MMTV) polyoma middle T antigen 
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(PyMT) transgenic mouse model that spontaneously de-
velop adenocarcinomas in the mammary gland. The mi-
metic peptide 4F increased tumor latency, decreased the 
mammary gland weight and total tumor burden compared 
with vehicle treatment. However, hapoA-I did not produ-
ce any effect on tumor onset and growth despite increa-
sing HDL-C. The anti-tumorigenic effects of 4F were closely 
associated with its ability to reduce the oxidized (ox) LDL 
(Cedo et al., 2016). Overexpression of hApoA-I also reduced 
the formation of oxLDL. However, the levels of 27-hydro-
xycholesterol (27-HC), a metabolite that has been reported 
to promote tumor growth in mouse models of ER-positive 
breast cancer (Nelson et al., 2013), were higher both in the 
serum and mammary tissue of PyMT-hApoA-I mice com-
pared to control mice. The expression of Cyp7b1, the main 
enzyme implicated in 27-HC catabolism, was downregula-
ted in mammary tissue of hApoA-I mice. This raised 27-HC 
could counteract the HDL-mediated benefits on the oxLDL 
levels and tumor progression and explain that the apoA-I 
mimetic peptide 4F, but not increased apoA-I-containing 
HDL levels, inhibits tumor growth in mice with inherited 
breast cancer. Our data are consistent with the reported 
anti-tumorigenic activity of apoA-I mimetics in other type 
of cancers (Cedo et al., 2016).
Immune response 
Mast cell activation and vascular permeability.
Mast cells are a type of white blood cell that function 
as a “master regulator” of the immune system. They are 
present in connective tissues around the body and in the 
arterial intima; mast cells have been found closely to ma-
crophage foam cells (Kaartinen et al., 1995). Mast cell ac-
tivation lead to a degranulation and chymase contained 
in its cytoplasm was able to modify HDL particles in vitro 
and to inhibit macrophage cholesterol efflux (Lee-Rueckert 
and Kovanen, 2006). We investigated whether local activa-
tion of mast cells would attenuate cholesterol efflux from 
neighboring macrophage foam cells, thereby disrupting the 
entire macrophage-to-feces RCT pathway (Lee-Rueckert 
et al., 2011). First, we demonstrated that the injection of 
mast cell-degranulating compound 48/80 in the peritoneal 
cavity of mice was able to inactivate by proteolysis the ac-
tivity of apoA-I as an ex vivo cholesterol acceptor. Then, we 
evaluated the effects of injecting 48/80 into the C57Bl/6J 
mice to induce peritoneal mast cell activation, hApoA-I to 
stimulate RCT, and [3H]-cholesterol labeled J774 macro-
phages for measurement of the rate of RCT. After 3 hours, 
[3H]-radioactivity was measured in the intestinal lumen. 
The hApoA-I stimulus on RCT was completely blocked in 
48/80-treated mice with competent mast cells. In mast 
cell-deficient mice this RCT stimulated by apoA-I is higher 
in 48/80-treated mice indicating that the impaired RCT rate 
in 48/80-treated wild type mice was mast cell-dependent. 
Pre-incubation hApoA-I with or without a mouse chymase 
and posterior injection to mouse confirmed that impaired 
RCT was a consequence of apoA-I proteolysis. Although the 
fragments of apoA-I in peritoneal fluid could not be identi-
fied due to their rapid clearance, the study allowed to va-
lidate the hypothesis that activation of mast cells causes 
apoA-I proteolysis, and as a result, there is a decrease in 
the RCT pathway (Lee-Rueckert et al., 2011).
The concentration of lipoprotein particles in the in-
terstitial fluid is the result of a dynamic balance between 
entry via the capillaries and the exit via lymphatic system 
(Miller et al., 2011). Skin and intimal layer of arteries are 
two key points for cholesterol accumulation and may sha-
re common pathogenic mechanisms. HDL is removed from 
interstitial fluids by the lymphatic system and it has been 
shown that variation in its flow may stimulate RCT (Mar-
tel et al., 2013). We have recently investigated whether an 
increased vascular permeability promotes RCT from skin. 
Therefore, we evaluated the effect of increased vascular 
permeability in the skin on the RCT rate from J774 foam 
cells injected into the dorsal subcutaneous layer of the skin 
(Kareinen et al., 2015). The increase of the subcutaneous 
levels of histamine promoted HDL influx to skin and acce-
lerated the rate of RCT from skin to feces. The treatment 
with different histamine-receptor antagonists indicate that 
the stimulatory effect of histamine on RCT was mainly me-
diated by histamine H1 receptor. These results were also 
found when other vasodilator agents were injected, such 
as serotonin and bradykinin. Exogenous administration of 
HDL and histamine in apoA-I deficient mice evidenced that 
the increase of circulating HDL levels and triggering of lo-
cal vascular permeability were both required to enhance 
macrophage RCT from subcutaneously located macropha-
ges. Importantly, the degranulation of activated mast cells 
releases a number of vasoactive components, including 
histamine, which was able to stimulate endogenously the 
RCT pathway (Kareinen et al., 2015). This contrasts with 
our previous findings that demonstrated the mast cell acti-
vation cause impaired macrophage-to-intestine RCT when 
hapoA-I was intraperitoneallly injected to stimulate RCT 
(Lee-Rueckert et al., 2011). The role of mast cell activati-
on may probably depend on the balance between vascular 
permeability and apoA-I proteolysis.
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Autoimmune arthritis 
The relationship between dyslipidemia and the inciden-
ce of CVD in patients affected by rheumatoid arthritis has 
been established but it is still the subject of intense debate 
(John and Kitas, 2012). ApoE and inflammatory immune res-
ponse are inversely correlated; however, the mechanism in-
volved in this process remains unclear (Postigo et al., 2011). 
We recently investigated the severity of one type of autoim-
mune arthritis, Collagen-II-autoimmune arthritis (CIA), in 
apoE-deficient mice. ApoE deficiency was associated with 
higher severity of CIA (Alvarez et al., 2016). Consistent with 
these findings, a significantly increase in the expression of 
arthritogenic Il1β, Tnfa and Il6 was observed in apoE-de-
ficient mice, thereby indicating that partial or total apoE 
deficiency modifies the polarization of macrophages after 
a potent inflammatory insult. ApoE-deficiency also altered 
the biochemical composition of HDL particles. However, 
the lipoprotein particles showed similar antioxidant ability, 
suggesting that the exacerbation of arthritis is largely inde-
pendent of HDL function. We analyzed the role of hyperc-
holesterolemia in the severity of CIA by using LDLR-deficient 
mice. The fact that CIA was more severe in apoE-deficient 
mice than in LDLR-deficient mice excludes that the LDLR is 
the mechanism by which ApoE modulates CIA severity. The-
se findings demonstrate that both hypercholesterolemia 
and ApoE, but not HDL function, regulate the intensity of 
systemic autoimmune response (Alvarez et al., 2016).
Diabesity
Patients with type 2 diabetes (T2D) show an increased 
risk for premature CVD and death (Mazzone et al., 2008). 
Most (~80%) of individuals with T2D are obese, highlighting 
the pivotal role of increased adiposity as a risk factor (Chadt 
et al., 2000). Plasma levels of lipids are also frequently alte-
red in both entities (Bays et al., 2013; Tchernof and Despres, 
2013), particularly, those of HDL which are often reduced 
(Kontush and Chapman, 2008). HDL are also dysfunctional in 
patients with T2D (Kontush and Chapman, 2008). Consistent-
ly, cholesterol efflux mediated by HDL from diabetic patients 
is markedly reduced (Apro et al., 2016). In relation to T2D, 
compelling experimental evidence suggests that the hepa-
tobiliary trafficking of cholesterol might be impaired in an 
animal model, the db/db mice, being in part associated with 
reduced hepatic levels of ABCG5 and G8. We have recently 
demonstrated that macrophage-to-feces RCT is impaired in 
db/db mice partly due to defects in the hepatic LXR signalling 
(Errico et al., 2017). In this case, RCT dynamics may be partly 
restored by a potent LXR agonist who induces Abcg5/g8. No-
tably, a commensurate favourable up-regulation in the he-
patic gene expression of these two transporters, and other 
known targets of LXRa, was also observed in obese patients 
subjected to bariatric surgery along with an improvement 
in their fatty liver phenotype. Additionally, reduced liver 
Abcg5/g8 protein abundance in db/db mice has been also 
partly explained by the participation of post-transcriptional 
mechanisms involving enhanced endoplasmic stress (Sabeva 
et al., 2009). Interestingly, the induction of LXR has been also 
reported to ameliorate ER stress induced by obesity and he-
patic lipid accumulation in vivo (Rong et al., 2013); potenti-
ally, this might help in the partial restoration of liver ABCG5/
G8 protein abundance in LXR-treated db/db mice. Taking to-
gether, these data might support the potential of targeting 
LXR signalling as a strategy to improve RCT in diabesity.
Dietary factors
Significant evidence has permitted to identify associati-
ons between serum HDL-C and diet, revealing a link betwe-
en different dietary factors and their potential effects on 
HDL-mediated atheroprotection (Escola-Gil et al., 2015)
Dietary fats
The content of the dietary fat plays a key role in the deve-
lopment of CVD and metabolic diseases, such as obesity, at-
herosclerosis and T2D. Dietary saturated fatty acids (SFA) in-
take is associated with an increased risk of CVD. Also, a direct 
relationship between high intake of SFA and HDL-C has been 
established from several epidemiological studies and one 
meta-analysis (Knuiman et al., 1987; Mensink et al., 2003; 
Kotseva et al., 2008). Conversely, polyunsaturated fatty acid 
(PUFA)  intake usually reduces HDL-C, even though they are 
potentially atheroprotective (Escola-Gil et al., 2015). 
We initially investigated the effect of a high–SFA, Wes-
tern-type diet, with or without added cholesterol, on the 
entire macrophage-to-feces RCT pathway in mice (Esco-
la-Gil et al., 2011). The high–SFA and cholesterol-contai-
ning diet caused a significant increase in plasma choleste-
rol, HDL-C, and liver cholesterol and accelerated the rate 
of macrophage-to-feces RCT by 3- to 4-fold. These effects 
were greatly reduced in mice fed the same high-SFA diet 
without added cholesterol. We also used humanized mice 
expressing human CETP and, similarly to the findings in wild-
type mice, the high–SFA and cholesterol-containing diet in-
duced a significant increase in fecal macrophage-derived 
[3H]-tracer excretion. The dietary stimulus on RCT was also 
almost totally absent in CETP transgenic mice fed with the 
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SFA diet without cholesterol. When we analyzed the diffe-
rent RCT steps, the serum from mice fed the high–SFA and 
cholesterol-containing diet had a higher ability to induce 
macrophage cholesterol efflux. Furthermore, the high–SFA 
and cholesterol-containing diet-fed mice showed an ac-
celerated excretion of fecal HDL-derived [3H]-cholesterol. 
The latter was completely blunted when mice were fed 
the diet without cholesterol. Importantly, only the high–
SFA and cholesterol-containing diet increased liver Abcg5/
g8 expression. We also found that this RCT increase was 
independent of other existing metabolic disarrangements 
such as obesity or insulin resistant. We concluded that the 
presence of dietary cholesterol and liver ABCG5/G8 trans-
porters is required for the SFA- and cholesterol-mediated 
induction of RCT. Since this diet also promoted atheroscle-
rosis, this change in RCT seems to constitute a compensa-
tory mechanism to protect macrophages from cholesterol 
accumulation (Escola-Gil et al., 2011).
Since the high–SFA and cholesterol-containing diet im-
pairs HDL antioxidant function, we investigated whether 
PUFA could correct the deleterious effects of SFA. We eva-
luated the effect of replacing dietary SFA by PUFA (mainly 
the linoleic and α-linolenic acids) on HDL antioxidant po-
tential and the macrophage-specific RCT pathway (Cedo et 
al., 2015).  The high-SFA diet caused a significant increase in 
serum HDL lipids and upregulated the levels of oxidized (ox)
HDL and oxLDL. Replacing dietary SFA with PUFA reverse the 
effects of SFA on HDL lipid levels and on lipoprotein oxidati-
on. The ability of HDL to reduce LDL oxidation was evalua-
ted by conjugated diene formation of LDL under prooxidant 
conditions in the presence of HDL. The results demonstrated 
that HDL from high-SFA and cholesterol-containing diet-fed 
mice showed an impaired ability to protect against  LDL oxi-
dation . Importantly, the PUFA-containing diet prevented 
the SFA-mediated impairment of HDL antioxidant function. 
The preferential action of PAF-AH on linoleic acid-containing 
phospholipids of oxidized lipoproteins might explain the 
higher ability of PUFA-fed mice HDL to prevent the onset of 
LDL oxidation. These PUFA-mediated changes in oxidized li-
poproteins were not associated with the insulin resistance. 
In contrast with the critical role of cholesterol on macropha-
ge-to-feces RCT, the amount of dietary PUFA did not affect 
the rate of RCT pathway in mice (Cedo et al., 2015). 
Phytosterols
Dietary phytosterols are able to reduce intestinal choles-
terol absorption and consequently decrease the LDL levels 
on serum (Calpe-Berdiel et al., 2009). Beyond this potential 
cardioprotective role in CVD, some epidemiological studies 
have suggested that phytosterols may have anti-tumorigenic 
properties (Berges et al., 1995). Some potential mechanisms 
include alteration in sterol metabolism which may affect 
cancer cell growth, apoptosis promotion and decreased an-
giogenesis (Bradford and Awad, 2010). We analyzed the role 
of phytosterol-supplemented diet in the tumor onset and 
progression in PyMT mice (Llaverias et al., 2013). A 2% phy-
tosterols supplement caused a significant delay in the deve-
lopment of hyperplasic mammary lesions and a decrease in 
total tumor burden in PYMT mice fed a high-fat, high-choles-
terol diet. Also, Cyclin D1, a tumor biomarker, was shown to 
be significantly decreased in PyMT transgenic mice fed the 
phytosterol supplement. However, phytosterols neither af-
fected the availability of cholesterol in the mammary gland 
nor altered the expression of the main cholesterol transpor-
ters. Importantly, phytosterols reduced HDL-peroxidation, 
thereby enhancing HDL antioxidant capacity. Decreased 
valules of Laudan GP indicated that this protection might be 
due to changes in the physicochemical properties of HDL, 
thereby increasing the packing of the surface lipids and pro-
moting lipoprotein resistance to oxidation. We concluded 
that dietary phytosterols caused a delay on breast tumor 
progression in the setting of a typical Western diet and sug-
gest that phytosterols may exert these anticancer effects by 
preventing oxidative damage. (Llaverias et al., 2013)
Methionine 
Methionine-rich foods can affect the plasma levels of 
homocysteine (Hcy), an intermediate metabolite of the fo-
lic acid pathway, causing a hyperhomocysteinemia (HHcy). 
HHcy induced by methionine can accelerate atherosclero-
tic progression and consequently has been considered a 
risk factor for CVD (Dayal and Lentz, 2008). Furthermore, 
HHcy has been associated to low levels of HDL-C in ani-
mal models and in humans (Liao et al., 2007; Vergeer et 
al., 2010). We determined the effect of HHcy induced by a 
methionine-rich diet on macrophage-to-feces RCT and on 
the ability of HDL to protect against LDL oxidation. Met-
hionine-induced HHcy in mice resulted in a significant de-
crease of HDL-C and apoA-I. The susceptibility of HDL to 
oxidation was enhanced in HHcy mice. This change was 
concomitant with an impaired ability of HDL to prevent 
LDL oxidative modification. Importantly, PON1 and PAF-AH 
activities, two of the main HDL-associated enzymes with 
antioxidant activity, were also reduced in HHcy mice. The 
ability of HDL to efflux cholesterol from macrophages was 
decreased in HHcy mice; however, dietary methionine did 
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not affect the macrophage-specific RCT measured as the 
output of macrophage-derived cholesterol into feces (Julve 
et al., 2013). Overall, our findings indicate that HHcy might 
exert at least part of its proatherogenic effect by impairing 
the antioxidant properties of HDL.
Resveratrol
Resveratrol, a natural polyphenolic compound, is 
found in foods such as the skin of grapes, blueberries, ras-
pberries and mulberries. Some cardioprotective properti-
es have been attributed to resveratrol, such as hypolipi-
demic, antioxidant and anti-inflammatory actions. Some 
studies in mice indicated that resveratrol may increase 
HDL-C and, consequently, inhibit atherosclerosis progres-
sion (Ramprasath and Jones, 2010). Resveratrol has also 
been identified as an activator of the NAD+-dependent 
deacetylase sirtuin1 (SIRT1), although resveratrol has not 
been proved to activate SIRT 1 directly. Therefore, both 
mechanisms may involve the modulation of LXR (Pacho-
lec et al., 2010). We investigated the ability of resveratrol 
and SIRT1 expression to induce LXR-target genes and the 
macrophage-specific RCT pathway in vivo (Escola-Gil et al., 
2013a). In contrast to the effects of the selective LXR-ago-
nist T0901317, no changes in liver cholesterol levels and 
intestinal cholesterol absorption were observed in mice 
given resveratrol at different doses. The highest resvera-
trol dose did not increase HDL-C while the LXR agonist did 
cause a significant increase. Further, SIRT1 expression in 
transgenic mice did not affect serum HDL-C and intestinal 
cholesterol absorption compared with wild-type. Howe-
ver, SIRT1 transgenic mice showed higher non-HDL and 
liver cholesterol content which has been attributed to ele-
vated liver lipogenesis (Qiang et al., 2011). As expected, 
mice treated with LXR-agonist presented a higher content 
of macrophage-derived [3H]-cholesterol in plasma and fe-
ces. However, macrophage-to-feces RCT rate was not af-
fected by the treatment of resveratrol. Even though SIRT1 
transgenic mice showed differences in the lipoprotein pro-
file, SIRT1 expression did not affect the magnitude of ma-
crophage RCT. Furthermore, the expression of LXR-target 
genes was unaffected by resveratrol. We concluded that 
resveratrol and SIRT1 expression did not promote the RCT 
pathway in vivo (Escola-Gil et al., 2013a).
Concluding remarks
Genetically engineered mouse models have been used 
extensively for investigating the role of different thera-
peutic approaches and the overexpression and deletion of 
HDL proteins involved in the major HDL cardioprotective 
functions. Current data have demonstrated that enhanced 
macrophage-to-feces RCT or HDL antioxidant functions are 
inversely correlated with atherosclerosis development. It 
should be noted that CETP expression did not affect ma-
jor antiatherogenic functions in mice (Rotllan et al., 2008), 
which is consistent with the results of 3 synthetic CETP in-
hibitors that failed to reduce CVD (Barter and Rye, 2012; 
Lee-Rueckert et al., 2016). However, a new CETP inhibitor, 
anacetrapib, substantially increased HDL-C and apoA-I, but 
also pre-β HDL particles and reduced CVD events (Bow-
man et al., 2017). At present, other HDL-based therapies, 
such as infusions of apoA-I mimetics or other reconstitu-
ted HDL particles for increasing apoA-I levels, appear to be 
promising tools in preclinical studies. Taken together, the 
available data indicate that increased HDL-C do not always 
correlate with enhanced HDL functions and, therefore, 
should not be considered a biomarker of HDL functionality. 
In humans, the efficiency of RCT has been evaluated with 
the surrogate parameter that indicates the ability of HDL to 
promote the first step of RCT, the macrophage cholesterol 
efflux capacity. Recent clinical data suggest that this para-
meter is a strong predictor of CVD in humans (Rohatgi et 
al., 2014; Saleheen et al., 2015).
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